These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 103434)

  • 21. An inside look at the UCLA P&T committee: how does it influence prescribing practices?
    Conolly ME
    Hosp Formul; 1986 Feb; 21(2):214-7. PubMed ID: 10275576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacy program to reduce parenteral nutrition costs.
    Roberts MJ; Teasley KM; Roberts AW
    Am J Hosp Pharm; 1981 Oct; 38(10):1519-20. PubMed ID: 6794366
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacy department costs and patient charges associated with a home parenteral nutrition program.
    Brakebill JI; Robb RA; Ivey MF; Christensen DB; Young JH; Scribner BH
    Am J Hosp Pharm; 1983 Feb; 40(2):260-3. PubMed ID: 6402929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albumin in TPN solutions: potential savings from a prospective review.
    Mirtallo JM; Schneider PJ; Ruberg RL
    JPEN J Parenter Enteral Nutr; 1980; 4(3):300-2. PubMed ID: 6772812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multidisciplinary process to determine, communicate, and manage an antibiotic formulary.
    Cook AA; Sanchez ML
    Hosp Pharm; 1992 Oct; 27(10):867-9, 872-4, 882. PubMed ID: 10121423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P & T Committee role in advocating rational therapeutics.
    Borreson R
    Hosp Formul; 1986 May; 21(5):590-8. PubMed ID: 10311625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating a restrictive formulary system by assessing nonformulary-drug requests.
    Green JA; Chawla AK; Fong PA
    Am J Hosp Pharm; 1985 Jul; 42(7):1537-41. PubMed ID: 4025350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlling financial variables--changing prescribing patterns.
    Abramowitz PW
    Am J Hosp Pharm; 1984 Mar; 41(3):503-15. PubMed ID: 6367444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth of bacteria and fungi in parenteral nutrition solutions containing albumin.
    Mirtallo JM; Caryer K; Schneider PJ; Ayers L; Fabri PJ
    Am J Hosp Pharm; 1981 Dec; 38(12):1907-10. PubMed ID: 6798862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical-pharmacological aspects, application and effectiveness of total parenteral nutrition in surgical patients.
    Dionigi R; Guaglio R; Bonera A; Cerri M; Rondanelli R; Campani M
    Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):107-18. PubMed ID: 107127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial formulary management: a case study in a teaching hospital.
    Wright DB
    Pharmacotherapy; 1991; 11(1 ( Pt 2)):27S-31S. PubMed ID: 2011570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishing an enteral product formulary.
    Ford DB; Bergerson SL; Henderson P; Murphy J; Peter J
    J Am Diet Assoc; 1989 May; 89(5):681-3. PubMed ID: 2498416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key inventory to formulary to cut drug costs.
    Schmieding JL; Sita MJ
    Hospitals; 1980 Sep; 54(17):78-81. PubMed ID: 7399457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions.
    Bullock L; Parks RB; Lampasona V; Mullins RE
    Am J Hosp Pharm; 1985 Dec; 42(12):2683-7. PubMed ID: 3936354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions.
    Bullock L; Fitzgerald JF; Glick MR; Parks RB; Schnabel JG; Hancock BG
    Am J Hosp Pharm; 1989 Nov; 46(11):2321-5. PubMed ID: 2511752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing the number of formulary theophylline preparations.
    Anandan JV
    Am J Hosp Pharm; 1981 Apr; 38(4):511-3. PubMed ID: 7282676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Parenteral nutrition in liver diseases].
    Wewalka F; Ferenci P; Lochs H
    Z Gesamte Inn Med; 1980 Oct; 35(20):753-8. PubMed ID: 6782775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.